
Liquidity, historical trends, and peer comparisons.
According to Immix Biopharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 25.13. This represents a change of 121.30% compared to the average of 11.36 of the last 4 quarters.
The mean historical Current Ratio of Immix Biopharma, Inc. over the last ten years is 17.10. The current 25.13 Current Ratio has changed 47.02% with respect to the historical average. Over the past ten years (40 quarters), IMMX's Current Ratio was at its highest in in the December 2021 quarter at 90.01. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
17.10
Median
5.32
Minimum
0.10
Maximum
90.01
Discovering the peaks and valleys of Immix Biopharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 89.03%
Maximum Annual Current Ratio = 90.01
Minimum Annual Increase = -87.00%
Minimum Annual Current Ratio = 0.10
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 10.01 | 330.66% |
| 2024 | 2.33 | -56.27% |
| 2023 | 5.32 | -54.56% |
| 2022 | 11.70 | -87.00% |
| 2021 | 90.01 | 89.03% |
| 2020 | 0.10 | -50.34% |
The current Current Ratio of Immix Biopharma, Inc. (IMMX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.88
5-year avg
23.87
10-year avg
17.10
Immix Biopharma, Inc.’s Current Ratio is greater than Nurix Therapeutics, Inc. (8.44), greater than Abivax S.A. (5.97), greater than MacroGenics, Inc. (2.96), greater than CytomX Therapeutics, Inc. (9.36), greater than NovaBridge Biosciences (7.64), greater than Arcus Biosciences, Inc. (3.34), greater than Celldex Therapeutics, Inc. (11.82), greater than Cardiff Oncology, Inc. (3.30), greater than Immunic, Inc. (5.05), greater than Immutep Limited (5.69),
| Company | Current Ratio | Market cap |
|---|---|---|
| 8.44 | $1.74B | |
| 5.97 | $7.51B | |
| 2.96 | $147.15M | |
| 9.36 | $512.06M | |
| 7.64 | $116.42M | |
| 3.34 | $2.43B | |
| 11.82 | $2.35B | |
| 3.30 | $67.60M | |
| 5.05 | $108.34M | |
| 5.69 | $21.74M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immix Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immix Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Immix Biopharma, Inc.'s Current Ratio?
How is the Current Ratio calculated for Immix Biopharma, Inc. (IMMX)?
What is the highest Current Ratio for Immix Biopharma, Inc. (IMMX)?
What is the 3-year average Current Ratio for Immix Biopharma, Inc. (IMMX)?
What is the 5-year average Current Ratio for Immix Biopharma, Inc. (IMMX)?
How does the current Current Ratio for Immix Biopharma, Inc. (IMMX) compare to its historical average?